Wednesday, 26 August 2026European Markets

NORDIC NANOVECTOR Stock Drops By 21% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of NORDIC NANOVECTOR (Oslo Børs All-share Index_GI: NANOV.OL) fell by a staggering 21.26% in 10 sessions from kr1.02 to kr0.80 at 16:39 EST on Tuesday, after three successive sessions in a row of losses. Oslo Børs All-share Index_GI is dropping 0.35% to kr1,410.94, after five sequential sessions in a row of losses.

NORDIC NANOVECTOR's last close was kr0.82, 94.8% below its 52-week high of kr15.78.

About NORDIC NANOVECTOR

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. The company has collaboration agreements with Paul Scherrer Institute; ArevaMed; LegoChem Bio; and Heidelberg Pharma. It also has a research collaboration with the University of Pennsylvania to generate a CD37-targeting CAR-T cell approach as a treatment for patients with B-cell malignancies. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, NORDIC NANOVECTOR has a trailing twelve months EPS of kr-4.377.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -155.9%.

Volatility

NORDIC NANOVECTOR's last week, last month's, and last quarter's current intraday variation average was a negative 2.55%, a negative 0.77%, and a positive 4.11%.

NORDIC NANOVECTOR's highest amplitude of average volatility was 2.55% (last week), 2.30% (last month), and 4.11% (last quarter).

Yearly Top and Bottom Value

NORDIC NANOVECTOR's stock is valued at kr0.80 at 16:39 EST, below its 52-week low of kr0.81.

More news about NORDIC NANOVECTOR (NANOV.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com